{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T-cell+Receptor-engineered+T-cells", "query": { "intervention": "T-cell Receptor-engineered T-cells" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 141, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T-cell+Receptor-engineered+T-cells&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-13T13:09:37.288Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06748872", "title": "EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Epithelial Ovarian Cancer", "Gastro-esophageal Junction Cancer", "Soft Tissue Sarcoma (STS)", "Myxoid Liposarcoma", "Synovial Sarcoma" ], "interventions": [ { "name": "Lymphodepletion", "type": "DRUG" }, { "name": "TCR-T cells (MDG1015)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Medigene AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2025-07-01", "completion_date": "2042-08-01", "has_results": false, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-09-13T13:09:37.288Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06748872" }, { "nct_id": "NCT01626495", "title": "Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B Cell Leukemia", "B Cell Lymphoma" ], "interventions": [ { "name": "CART-19", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "24 Years", "sex": "ALL", "summary": "1 Year to 24 Years" }, "enrollment_count": 73, "start_date": "2011-08-17", "completion_date": "2019-07-11", "has_results": true, "last_update_posted_date": "2020-03-23", "last_synced_at": "2026-09-13T13:09:37.288Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01626495" }, { "nct_id": "NCT05066165", "title": "Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Arm 1: NTLA-5001", "type": "GENETIC" }, { "name": "Arm 2: NTLA-5001", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Intellia Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2021-12-17", "completion_date": "2022-08-31", "has_results": true, "last_update_posted_date": "2023-12-28", "last_synced_at": "2026-09-13T13:09:37.288Z", "location_count": 6, "location_summary": "Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Portland", "state": "Oregon" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05066165" }, { "nct_id": "NCT03441100", "title": "TCR-engineered T Cells in Solid Tumors: IMA202-101", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Refractory Cancer", "Recurrent Cancer", "Cancer" ], "interventions": [ { "name": "IMA202 Product", "type": "DRUG" }, { "name": "IMADetect®", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Immatics US, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2019-05-02", "completion_date": "2023-03-17", "has_results": false, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-09-13T13:09:37.288Z", "location_count": 2, "location_summary": "Pittsburgh, Pennsylvania • Houston, Texas", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03441100" }, { "nct_id": "NCT05359211", "title": "NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Grade 3b Follicular Lymphoma", "Recurrent Primary Mediastinal Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory Grade 3b Follicular Lymphoma", "Refractory Primary Mediastinal Large B-Cell Lymphoma", "Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Lisocabtagene Maraleucel", "type": "BIOLOGICAL" }, { "name": "Polymer-conjugated IL-15 Receptor Agonist NKTR-255", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2022-12-08", "completion_date": "2026-09-04", "has_results": false, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-09-13T13:09:37.288Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05359211" }, { "nct_id": "NCT00610311", "title": "Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Skin Cancer" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "ALVAC gp100 Vaccine", "type": "BIOLOGICAL" }, { "name": "anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2008-01", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2015-10-28", "last_synced_at": "2026-09-13T13:09:37.288Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00610311" }, { "nct_id": "NCT07513194", "title": "GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Atypical Teratoid Rhabdoid Tumor", "Central Nervous System Rhabdoid Tumor" ], "interventions": [ { "name": "21.15.GPC3-CAR T Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 21, "start_date": "2026-09-01", "completion_date": "2044-10-31", "has_results": false, "last_update_posted_date": "2026-04-07", "last_synced_at": "2026-09-13T13:09:37.288Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07513194" }, { "nct_id": "NCT04536922", "title": "Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic HPV-16 Positive Squamous Cell Anal Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA(R))", "type": "DRUG" }, { "name": "Individual Patient TCR-Transduced PBL", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2021-01-27", "completion_date": "2021-01-27", "has_results": false, "last_update_posted_date": "2021-02-01", "last_synced_at": "2026-09-13T13:09:37.288Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04536922" }, { "nct_id": "NCT04227275", "title": "A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "CART-PSMA-TGFβRDN", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Anakinra", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Tceleron Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 16, "start_date": "2019-11-22", "completion_date": "2022-11-07", "has_results": false, "last_update_posted_date": "2023-08-21", "last_synced_at": "2026-09-13T13:09:37.288Z", "location_count": 9, "location_summary": "Tampa, Florida • Kansas City, Kansas • St Louis, Missouri + 5 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04227275" }, { "nct_id": "NCT03912831", "title": "Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer" ], "interventions": [ { "name": "KITE-439", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2019-04-30", "completion_date": "2022-02-18", "has_results": true, "last_update_posted_date": "2023-12-26", "last_synced_at": "2026-09-13T13:09:37.288Z", "location_count": 9, "location_summary": "Gilbert, Arizona • Duarte, California • Los Angeles, California + 6 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03912831" } ] }